Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-27T08:34:13.804Z Has data issue: false hasContentIssue false

Antibiotic Use in Developing Countries

Published online by Cambridge University Press:  02 January 2015

Raúl E. Istúriz*
Affiliation:
Groupe Hospitaller Bichat-Claude Bernard, Paris, France
Claude Carbon
Affiliation:
Groupe Hospitaller Bichat-Claude Bernard, Paris, France
*
Groupe Hospitaller Bichat-Claude Bernard, 46, rue Henri Huchard, 75877 Paris Cedex 18, France

Abstract

Antimicrobials have been used successfully for over 6 decades, but genes expressing resistance to them have emerged in strains of bacteria and have disseminated through the global ecosystem to reach infecting microorganisms, produce disease, and seriously interfere with therapy, allowing infections to progress and kill despite antibiotic administration. The upsurge in prevalence of such resistance genes in the bacterial population that colonize and infect humans involves two processes, emergence and dissemination, in both of which there have been contributions from the developing world, where resistance is common and increasing. The emergence of pneumococcal isolates noted in Papua New Guinea and later in South Africa that 1 decade later spread to most of the world and the intercontinental spread between the United States and Venezuela of a new gentamicin resistance gene carried on an epidemic plasmid are examples of the ability of bacteria to travel freely, without regard to borders. Complex societal issues such as the misuse of antibiotics by physicians, pharmacists, and the public; the suboptimal quality of the drugs (emergence); and conditions such as crowding, lack of hygiene, poor or nonexistent hospital infection control practices, or insufficient surveillance (dissemination) play a largely unmeasured role that requires study and solutions. In the meantime, we may intervene to delay the emergence of resistance and to limit its spread by promoting the judicious use of antibiotics both at the local level as well as from multinational organized cooperative efforts. Education and improvement of surveillance and socioeconomic conditions are integral parts of any solution strategy.

Type
Reviews
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. O'Brien, TF. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997;24(suppl 1):S2S8.Google Scholar
2. Gwatkin, DR, Guillot, M. The Burden of Disease Among the Global Poor. Current Situation, Future Trends, and Implications for Strategy. Washington, DC: The World Bank; 2000. Health, Nutrition and Population Series.Google Scholar
3. World Health Organization. A review of world antibacterial consumption. Geneva, Switzerland: WHO. In press.Google Scholar
4. Col, NF, O'Connor, RW. Estimating worldwide current antibiotic usage: report of Task Force 1. Rev Infect Dis 1987;9(suppl 3):S232S243.Google Scholar
5. Okeke, IN, Lamikanra, A, Edelman, R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999;5:1827.Google Scholar
6. Hart, CA, Kariuki, S. Antimicrobial resistance in developing countries. BMJ 1998;317:647650.Google Scholar
7. World Health Organization. Public-Private Roles in the Pharmaceutical Sector. Implications for Equitable Access and Rational Drug Use. Health Economics and Drugs. DAP series no. 5; 1997:4565.Google Scholar
8. Hossain, MM, Glass, RI, Khan, MR. Antibiotic use in a rural community in Bangladesh. Int J Epidemiol 1982;11:402405.Google Scholar
9. Sauerborn, R, Ibrango, I, Nougtara, A, Borchert, M, Hien, M, Benzler, J, et al. The economic cost of illness for rural households in Burkina Faso. Trap Med Parasitol 1995;46:5460.Google Scholar
10. Tudor, SK, Amarasiri, MW, Wijekoon, TM. Access to Western drugs, medical pluralism, and choice of therapy in an urban, low income community of Sri Lanka. In: Etkin, NL, Tan, ML, eds. Medicines: Meaning and Context. Quezon City, Philippines: Health Action Information Network; 1994:185208.Google Scholar
11. World Health Organization. Containing Antimicrobial Resistance. WHO/CDS/CSR/DRS/99.2. Geneva, Switzerland: WHO; 1999. http://www.who.int/emc-documents/antimicrobial_resistance/docs/whocdscsrdrs992.pdf.Google Scholar
12. Guzman-Blanco, MG, Casellas, JM, Sader, HS. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin North Am 2000;14:6782.Google Scholar
13. Galimand, M, Guiyoule, A, Gerbaud, G, Rasoamanana, B, Chanteau, S, Carniel, E, et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997;337:677680.Google Scholar
14. Couper, MR. Strategies for the rational use of antimicrobials. Clin Infect Dis 1997;24(suppl 1):S154S156.Google Scholar
15. Schwartz, B. Preventing the spread of antimicrobial resistance among bacterial respiratory pathogens in industrialized countries. The case for judicious antimicrobial use. Clin Infect Dis 1999;28:211213.Google Scholar
16. Polk, R. Optimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999;29:264274.Google Scholar
17. Dowell, SF, Marcy, SS, Phillips, WR, et al. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 1998;101:163184.Google Scholar
18. Carbon, C, Bax, R. Regulating the use of antibiotics in the community. BMJ 1998;317:663665.Google Scholar